Plain-English translation of NCT06717113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called PET/CT that is designed to detect multiple myeloma, a cancer of plasma cells in the bone marrow. The scan uses a special radioactive tracer that targets a marker called BCMA, which appears on cancer cells. This new scan is being compared to an older imaging method to see if it can diagnose the disease more accurately and help doctors personalize treatment.
Multiple myeloma is hard to diagnose because it currently requires painful bone marrow biopsies, and choosing the wrong biopsy location can miss the disease. The new treatment approach targets BCMA, a protein on cancer cells, so this trial is testing whether the new imaging scan can identify this protein and help doctors catch the disease earlier and plan better personalized treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the new imaging scan ( PET/CT) and possibly also an older type of imaging scan ( PET/CT) so the researchers can compare how well each one works. The scan itself is non-invasive and similar to other medical imaging you may have had. Your participation would help doctors develop a better, less painful way to diagnose and treat multiple myeloma.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China